📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 16:23
712 analysed today
712
Today
133,601
All-time analysed
40,124
Positive
6,284
Negative
79,373
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
Jagsonpal Q1 FY27: 22% PAT Growth and Rs 25 Cr Aequitas Healthcare Acquisition
Jagsonpal Pharmaceuticals (JPL) reported a strong Q1 FY27 with 9% sales growth and 22% PAT growth, outperforming the industry growth rate of 11.6% by reaching 18.9% (Pharmarack data). The company completed the acquisition of Aequitas Healthcare for an enterprise value of Rs 25 crore, providing entry into the hospital segment with a business that generated Rs 53 crore in FY26. A Rs 40 crore share buyback was also concluded, which improved the Return on Capital Employed (ROCE) by 340 bps. Management is pivoting the portfolio toward high-margin semi-chronic and specialty therapies while maintaining an asset-light, outsourced manufacturing model.
Confidence: HIGH
What changedJagsonpal has formally entered the hospital segment through the Aequitas acquisition and completed a capital return to shareholders via a buyback.
Why it mattersThe shift toward semi-chronic and specialty therapies, combined with an asset-light model, is designed to drive higher margins and better capital efficiency (ROCE).
Q1 PAT Growth: 22%Aequitas Acquisition Value: Rs 25 crAequitas FY26 Revenue: Rs 53 crBuyback Amount: Rs 40 crROCE Improvement: 340 bps
📅 Short termThe stock may react positively to the earnings outperformance and the successful completion of the buyback, reflecting improved operational discipline.
📈 Long termThe structural shift to a brand-centric, specialty-focused model and the addition of a hospital vertical could lead to sustained margin expansion over the next 2-3 years.
⚠ Risk flags
- Lower gross margins in the hospital business (Aequitas) compared to branded prescriptions
- High brand concentration with top 5 brands contributing 54% of revenue
Key Highlights
Q1 FY27 PAT grew by 22% and Operating EBITDA increased by 21% year-on-year.
Acquired Aequitas Healthcare at an enterprise value of Rs 25 crore, adding Rs 53 crore in annual revenue (FY26).
Completed a Rs 40 crore share buyback at a 40% premium, which was oversubscribed 3.67 times.
Power brand portfolio grew by 19% compared to the broader market growth of 16%.
Inventory turnover ratio improved significantly to 17.6 in FY25 from 13.9 in FY24.
👀 What to Watch
Investors should monitor the integration of Aequitas Healthcare, specifically how it impacts overall gross margins given the lower-margin nature of hospital-segment sales. Watch for the company's ability to maintain its target of 1.5x industry growth through its new specialty therapy launches.
9% Q1 Revenue Growth and Rs 25 Cr Aequitas Acquisition to Drive Hospital Segment Entry
Jagsonpal Pharmaceuticals (JPL) reported a 9% sales growth for Q1 FY27, with EBITDA and PAT growing faster at 21% and 22% respectively. A key highlight is the Rs 25 Cr acquisition of Aequitas Healthcare, which brings Rs 53 Cr in FY26 revenue and provides immediate access to the hospital segment. The company also completed a Rs 40 Cr share buyback, which was oversubscribed 3.67x and improved ROCE by 340 bps. Management aims to maintain growth at 1.5x the industry rate by shifting focus toward high-margin semi-chronic and specialty therapies.
Confidence: HIGH
What changedJPL has moved from a stabilization phase to an expansion phase, marked by its first major acquisition (Aequitas) and a successful capital return to shareholders via buyback.
Why it mattersThe acquisition of Aequitas (Rs 53 Cr revenue) is highly material relative to JPL's TTM revenue of Rs 73 Cr, effectively scaling the business and diversifying its reach into hospital formularies.
Q1 Sales Growth: 9%Aequitas Acquisition Value: Rs 25 CrAcquisition vs TTM Revenue: ~34.2%Buyback Amount: Rs 40 CrROCE Improvement: 340 bpsAequitas FY26 Revenue: Rs 53 Cr
📅 Short termThe stock may react positively to the earnings outperformance relative to the industry and the successful completion of the buyback which signals management confidence.
📈 Long termThe shift toward an asset-light, branded-specialty model and the entry into hospital segments through Aequitas could structurally improve the company's scale and return profile over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Lower gross margins in the hospital segment compared to branded retail
- High brand concentration (Top 5 brands contribute ~54% of revenue)
- Dependency on contract manufacturers for quality and supply
Key Highlights
Q1 FY27 sales grew 9%, while operating EBITDA and Net Profit increased by 21% and 22% respectively.
Acquired Aequitas Healthcare for an enterprise value of Rs 25 Cr, representing ~34% of JPL's TTM revenue.
JPL's Pharmarack growth of 18.9% significantly outperformed the industry growth of 11.6% during the quarter.
Completed a Rs 40 Cr share buyback at a 40% premium to the then-market price, improving capital efficiency.
Power brand portfolio grew at 19% vs market growth of 16%, with 5 brands now ranking #1 in their molecules.
👀 What to Watch
Investors should monitor the integration of Aequitas Healthcare, specifically how it impacts overall gross margins given the lower-margin nature of the hospital segment. Watch for the execution of the 'semi-chronic' shift and whether the company can sustain its 1.5x industry growth target.
Jagsonpal Q1 FY27: PAT up 22% to ₹13.2 Cr; EBITDA Margins Expand to 23.2%
Jagsonpal Pharmaceuticals reported a strong start to FY27 with Q1 revenue growing 8.8% YoY to ₹82.2 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth. Profitability saw significant improvement as PAT rose 22.2% YoY to ₹13.2 Cr, supported by a 241 bps expansion in EBITDA margins to 23.2%. The company completed the 85% acquisition of Aequitas Healthcare, marking its entry into the hospital supplies segment. Despite a ₹40 Cr share buyback, the company remains cash-rich with ₹170 Cr in reserves.
Confidence: HIGH
What changedThe company has successfully entered the hospital supplies segment through the Aequitas acquisition and improved its market ranking to #88 in the IPM.
Why it mattersThe expansion into hospital supplies and the continued margin improvement through an asset-light model (outsourced manufacturing) demonstrate a shift toward higher capital efficiency and diversified revenue streams.
Q1 Revenue: ₹82.2 CrPAT Growth (YoY): 22.2%EBITDA Margin: 23.2%Cash Reserves: ₹170 CrBuyback Value vs Net Worth: 14.5%Aequitas Revenue Base: ₹53.3 Cr
📅 Short termThe stock may react positively to the margin expansion and the successful completion of the buyback and acquisition, reflecting disciplined capital allocation.
📈 Long termThe transition to a 'double-engine' growth model (retail + hospital) and the asset-light strategy could structurally improve ROCE, which already saw a 340 bps improvement this quarter.
⚠ Risk flags
- High brand concentration (Top 10 brands contribute 63% of sales)
- Dependency on contract manufacturers for quality standards
- Regulatory price controls affecting 6-7% of the portfolio
Key Highlights
Revenue grew 8.8% YoY to ₹82.2 Cr, with Pharmarack reporting 18.9% growth for the company vs 11.6% for the IPM.
Operating EBITDA increased 21.4% YoY to ₹19.1 Cr, driven by improved Medical Representative (MR) productivity.
PAT rose 22.2% YoY to ₹13.2 Cr, with net profit margins expanding by 176 bps to 16.0%.
Completed 85% acquisition of Aequitas Healthcare (revenue base ₹53.3 Cr) to enter the hospital business.
Maintained a robust cash balance of ₹170 Cr even after completing a ₹40 Cr share buyback during the quarter.
👀 What to Watch
Investors should monitor the integration of Aequitas Healthcare and its impact on margins, as management targets ₹10 Cr+ EBITDA from this segment by Year 2. Watch for the sustainability of the 23%+ EBITDA margins and the performance of the top 10 brands which contribute 63% of sales.
Jagsonpal Pharma Q1 PAT up 22% to ₹13.2 Cr; Enters Hospital Segment via Aequitas Acquisition
Jagsonpal Pharmaceuticals reported a strong Q1 FY27 with revenue growing 8.8% YoY to ₹82.2 Cr and PAT rising 22.2% to ₹13.2 Cr. The company achieved significant margin expansion, with Operating EBITDA margins climbing 241 bps to 23.2%, driven by improved Medical Representative productivity. Strategically, the company completed the acquisition of an 85% stake in Aequitas Healthcare, marking its entry into the hospital supplies market. Despite a ₹40 Cr share buyback, the company remains cash-rich with ₹170 Cr in reserves to fund further inorganic growth.
Confidence: HIGH
What changedJagsonpal has transitioned into the hospital supplies segment through the Aequitas acquisition and successfully improved its operating margins through better sales force efficiency.
Why it mattersThe company is successfully executing an asset-light model (outsourced manufacturing) while using its strong cash position for inorganic expansion, which has already led to a 340 bps improvement in ROCE.
Q1 Revenue: ₹82.2 CrQ1 PAT: ₹13.2 CrAequitas Revenue Base: ₹53.3 CrAequitas Revenue vs Q1 Revenue: ~64.8%Cash Reserves: ₹170 CrEBITDA Margin: 23.2%
📅 Short termThe stock is likely to react positively to the margin expansion and the clear growth roadmap provided by the Aequitas acquisition.
📈 Long termThe shift toward a 'double-engine' growth strategy (organic brands + hospital supplies) and an asset-light model positions the company for structural margin improvements and higher capital efficiency.
⚠ Risk flags
- High brand concentration (Top 10 brands contribute 63% of sales)
- Dependency on contract manufacturers for quality standards
- Regulatory price controls affecting 6-7% of the portfolio
Key Highlights
Revenue grew 8.8% YoY to ₹82.2 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 11.6% with a 18.9% internal growth rate.
Operating EBITDA increased 21.4% YoY to ₹19.1 Cr, with margins expanding to 23.2% from 20.8% in the previous year.
PAT reached ₹13.2 Cr, a 22.2% YoY increase, maintaining a healthy net margin of 16.0%.
Acquired 85% stake in Aequitas Healthcare, which brings a revenue base of ₹53.3 Cr and a target of ₹10+ Cr EBITDA by Year 2.
Maintained a robust cash balance of ₹170 Cr even after deploying ₹40 Cr for a share buyback during the quarter.
👀 What to Watch
Investors should monitor the integration of Aequitas Healthcare and its impact on consolidated margins starting from H2 FY27. Additionally, track the productivity of the 1,000+ member sales force and the performance of the top 10 brands which contribute 63% of sales.
Rs 4 Dividend: Jagsonpal Pharmaceuticals Sets September 04, 2026 as Record Date
Jagsonpal Pharmaceuticals has finalized September 04, 2026, as the record date for a final dividend of Rs 4 per equity share (200% of face value). This follows the Board's recommendation on April 27, 2026, for the FY ended March 31, 2026. The dividend is subject to shareholder approval at the 47th Annual General Meeting (AGM) scheduled for September 18, 2026. At the current market price of Rs 229.1, the dividend represents a yield of approximately 1.75%.
Confidence: HIGH
What changedThe company has moved from a dividend recommendation to fixing the specific timeline for the record date and shareholder meeting.
Why it mattersThis provides certainty on the timing of cash returns to shareholders. Notably, the Rs 4 dividend is higher than the reported TTM EPS of Rs 1.67, indicating a high payout ratio from reserves or accumulated profits.
Dividend per share: Rs 4Dividend Yield: ~1.75%Record Date: September 04, 2026AGM Date: September 18, 2026TTM EPS: Rs 1.67
📅 Short termThe stock may experience mild buying interest as the record date approaches, given the 1.75% yield.
📈 Long termLimited structural impact; the company's long-term value remains tied to its asset-light model and the success of new product launches like Dydrogesterone.
⚠ Risk flags
- Dividend payout exceeds current TTM earnings per share
Key Highlights
Dividend of Rs 4 per equity share of face value Rs 2 (200% payout)
Record date fixed for September 04, 2026, to determine shareholder eligibility
47th Annual General Meeting (AGM) to be held on September 18, 2026
Dividend payment to be processed within 30 days of AGM approval
Dividend amount (Rs 4) significantly exceeds the TTM EPS of Rs 1.67
👀 What to Watch
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one business day prior to the September 04 record date). Monitor the AGM outcome on September 18 for formal approval.
22% YoY Profit Growth in Q1; Rs 20.8 Cr Acquisition of Aequitas Healthcare
Jagsonpal Pharmaceuticals reported a 22.1% YoY increase in net profit to Rs 13.19 Cr for Q1 FY27, supported by an 8.7% growth in revenue to Rs 82.23 Cr. The company executed a Share Purchase Agreement to acquire an 85% stake in Aequitas Healthcare for Rs 20.8 Cr, representing approximately 7.5% of its net worth. Additionally, a Rs 40 Cr buyback of 1.6 million shares at Rs 250 per share was completed during the quarter. Operational performance remained strong with Profit Before Tax rising 22.5% YoY to Rs 17.68 Cr.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and confirmed the completion of a strategic acquisition and a share buyback program.
Why it mattersThe acquisition aligns with the company's strategy to expand its portfolio through M&A, while the buyback and profit growth indicate strong cash flow and capital allocation efficiency.
Revenue (Q1 FY27): Rs 82.23 CrNet Profit (Q1 FY27): Rs 13.19 CrAcquisition Value: Rs 20.8 CrAcquisition vs Net Worth: ~7.5%Buyback Price: Rs 250 per shareEPS (Q1 FY27): Rs 1.98
📅 Short termThe stock may react positively to the 22% profit growth and the fact that the buyback was executed at a premium to the current market price.
📈 Long termThe company's shift toward an asset-light, M&A-driven growth model (e.g., Yash Pharma, Aequitas) is structurally positive for ROCE and scaling without heavy capital expenditure.
⚠ Risk flags
- High brand concentration (top 5 brands contribute ~54% of revenue)
- Dependency on contract manufacturers for quality standards
- Regulatory price controls on 6-7% of the portfolio
Key Highlights
Revenue from operations increased 8.7% YoY to Rs 82.23 Cr from Rs 75.61 Cr
Net profit grew 22.1% YoY to Rs 13.19 Cr compared to Rs 10.80 Cr in the previous year
Acquisition of 85% stake in Aequitas Healthcare for Rs 20.8 Cr finalized in July 2026
Completed buyback of 1,600,000 equity shares at Rs 250 per share for a total of Rs 40 Cr
Employee benefit expenses rose 17.2% YoY to Rs 22.78 Cr
👀 What to Watch
Monitor the integration of Aequitas Healthcare and its contribution to consolidated margins in the upcoming quarters, and track the impact of the new Labour Code rules on employee costs.
Jagsonpal Pharmaceuticals Completes 85% Stake Acquisition in Aequitas Healthcare
Jagsonpal Pharmaceuticals has officially completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited as of July 17, 2026. This follows the initial proposal announced on June 29, 2026, and subsequent updates in early July. The move aligns with the company's strategy to drive growth through strategic acquisitions, complementing its existing portfolio in the Indian Pharmaceutical Market. Given the company's TTM revenue of Rs 73 Cr, this majority stake acquisition is a significant step in its inorganic expansion roadmap.
Confidence: HIGH
What changedThe proposed acquisition of Aequitas Healthcare has transitioned from a proposal to a completed transaction, making Aequitas a subsidiary of Jagsonpal Pharmaceuticals.
Why it mattersThis is a major execution milestone for Jagsonpal's inorganic growth strategy. For a company with a relatively small revenue base (Rs 73 Cr), acquiring a majority stake in another healthcare entity can significantly alter its growth trajectory and market reach.
Equity stake acquired: 85%Completion date: July 17, 2026TTM Revenue: Rs 73 CrMarket Cap: Rs 1488 CrPromoter Holding: 69.4%
📅 Short termThe completion of the deal is likely to be viewed positively by the market as it demonstrates management's ability to execute on its M&A pipeline.
📈 Long termThis acquisition could be structurally significant, helping the company outpace the industry growth rate of 7.5% and diversify its brand concentration risk.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of the new entity
- Lack of disclosed acquisition valuation in this specific filing
- Potential impact on cash reserves
Key Highlights
Completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited.
The transaction was finalized on July 17, 2026, following the initial announcement on June 29, 2026.
The acquisition supports the company's asset-light model and 'double-engine' leadership strategy.
Jagsonpal operates with a TTM revenue of Rs 73 Cr and a market cap of Rs 1488 Cr, making this a material expansion.
👀 What to Watch
Investors should monitor the next quarterly financial statement to assess the consolidation impact of Aequitas on Jagsonpal's top-line and OPM. Key details to watch include the final acquisition cost and the specific therapeutic segments Aequitas brings to the portfolio.
Jagsonpal Pharmaceuticals Completes 77.21% Stake Acquisition in Aequitas Healthcare
Jagsonpal Pharmaceuticals has finalized the acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited as of July 8, 2026. This follows a series of disclosures starting June 29, 2026, where the company initially proposed an 85% stake purchase. While the current acquisition is slightly lower than the original 85% target, it represents a controlling interest and aligns with the company's strategy of inorganic growth. The financial consideration for this transaction was not disclosed in the current filing.
Confidence: HIGH
What changedJagsonpal has transitioned from a proposed acquisition to a completed majority stake (77.21%) in Aequitas Healthcare.
Why it mattersGiven Jagsonpal's relatively small TTM revenue of ₹73 Cr, a majority acquisition is highly material and could significantly scale the business, consistent with its asset-light growth strategy.
Stake acquired: 77.21%Proposed stake: 85%TTM Revenue: ₹73 CrMarket Cap: ₹1538 Cr
📅 Short termThe completion of the acquisition is likely to be viewed positively by the market as a sign of management's execution on its growth roadmap.
📈 Long termThis acquisition is structurally significant as it expands the company's footprint in the Indian Pharmaceutical Market; long-term success depends on integration and MR productivity improvements.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Acquisition cost not disclosed
- Integration risk of the new entity
- Shortfall from the original 85% stake target
Key Highlights
Completed the acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited.
The acquisition is part of a previously announced plan to acquire up to an 85% stake.
The transaction was finalized on July 8, 2026, following disclosures on June 29 and July 7.
The move supports the company's 'three-pronged strategy' focusing on strategic acquisitions to expand its portfolio.
👀 What to Watch
Investors should monitor upcoming quarterly results to assess the revenue and margin contribution from Aequitas, and look for disclosures regarding the acquisition cost to evaluate the valuation paid.
69.77% Stake Acquired: Jagsonpal Pharmaceuticals Completes Majority Stake in Aequitas Healthcare
Jagsonpal Pharmaceuticals has completed the acquisition of a 69.77% stake in Aequitas Healthcare Private Limited, making it a subsidiary. This is part of a previously announced plan to acquire a total 85% stake in the company. Given Jagsonpal's TTM revenue of Rs 73 Cr, this acquisition is a significant move in its inorganic growth strategy. The company continues to follow an asset-light model, prioritizing brand and company acquisitions over physical manufacturing expansion.
Confidence: HIGH
What changedJagsonpal has transitioned from a proposed acquisition to a completed majority stake (69.77%) in Aequitas Healthcare, officially making it a subsidiary.
Why it mattersThis is a material acquisition for a company with Rs 73 Cr TTM revenue, supporting its strategy to expand its portfolio in segments like Gynaecology and Orthopaedics through an asset-light, M&A-driven approach.
Stake acquired: 69.77%Total proposed stake: 85%TTM Revenue: Rs 73 CrMarket Cap: Rs 1511 CrDebt: Rs 8 Cr
📅 Short termPositive sentiment is expected as the company demonstrates execution of its inorganic growth strategy.
📈 Long termThis acquisition is structurally significant for scaling the business and could lead to a re-rating if Aequitas contributes meaningfully to the top and bottom lines.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of the new subsidiary
- Acquisition cost not disclosed in this specific update
- Reliance on contract manufacturing for the expanded portfolio
Key Highlights
Completed the acquisition of a 69.77% equity stake in Aequitas Healthcare Private Limited.
Aequitas Healthcare has officially become a subsidiary of Jagsonpal Pharmaceuticals as of July 7, 2026.
The company intends to acquire a total of 85% stake in Aequitas, leaving ~15.23% to be completed.
The acquisition aligns with the company's strategy to outpace the Indian Pharmaceutical Market growth (7.5% in Q2 FY26).
👀 What to Watch
Investors should monitor the upcoming quarterly results to see the financial consolidation of Aequitas and watch for the completion of the remaining 15.23% stake acquisition.
Rs 20.8 Cr Acquisition: Jagsonpal to Acquire 85% Stake in Aequitas Healthcare
Jagsonpal Pharmaceuticals has signed a definitive agreement to acquire an 85% stake in Mumbai-based Aequitas Healthcare for Rs 20.8 crores. Aequitas reported revenues of Rs 53 crores in FY26, which is highly material as it represents approximately 72.6% of Jagsonpal's TTM revenue of Rs 73 crores. The acquisition marks Jagsonpal's strategic entry into the hospital segment, which currently accounts for ~10% of the Indian pharmaceutical market. The deal is funded through internal accruals and is expected to close by July 15, 2026.
Confidence: HIGH
What changedJagsonpal is expanding from a legacy retail prescription-focused player into the institutional hospital segment through a majority stake acquisition.
Why it mattersThe acquisition provides a massive inorganic revenue boost (over 70% of current TTM revenue) and grants immediate access to major hospital chains across India, diversifying the company's sales channels.
Acquisition Value: Rs 20.8 crTarget Revenue (FY26): Rs 53 crTarget Revenue vs TTM Revenue: ~72.6%Stake Acquired: 85%Expected Closing Date: July 15, 2026
📅 Short termThe market is likely to react positively to the significant revenue addition and the attractive valuation (implied 100% EV/Sales of ~0.46x).
📈 Long termThis is a structurally transformative move that could significantly scale the business and reduce dependence on retail brands, provided integration and institutional relationships are managed effectively.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of a new business segment
- Potential margin dilution if the hospital distribution business has lower OPM than the core business
Key Highlights
Acquiring 85% equity stake in Aequitas Healthcare for a total consideration of Rs 20.8 crores.
Aequitas FY26 revenue of Rs 53 crores is equivalent to ~72.6% of Jagsonpal's current TTM revenue.
Strategic entry into the hospital segment, moving the company toward an omnichannel specialty healthcare model.
Transaction to be funded entirely through internal accruals; company has low debt of Rs 8 crores.
Expected completion date for the transaction is July 15, 2026.
👀 What to Watch
Watch for the completion of the transaction by mid-July and subsequent consolidated financial results to assess the margin profile of the new hospital business compared to Jagsonpal's current 22.3% OPM.
₹20.8 Cr Acquisition: Jagsonpal to Acquire 85% Stake in Aequitas Healthcare
Jagsonpal Pharmaceuticals (JPL) has entered a definitive agreement to acquire an 85% stake in Aequitas Healthcare for ₹20.8 crore in cash. Aequitas is a hospital-focused pharmaceutical distributor with FY26 revenue of ₹53.31 crore, which represents a significant ~73% of JPL's TTM revenue of ₹73 crore. The acquisition, funded through internal accruals, marks JPL's strategic entry into the institutional hospital segment. The transaction is expected to conclude by July 15, 2026, with the target's current directors retaining a 15% stake.
Confidence: HIGH
What changedJagsonpal is transitioning from a legacy retail-focused prescription player to an omnichannel specialty healthcare business by acquiring a majority stake in a hospital distribution specialist.
Why it mattersThis is a highly material acquisition for a company of Jagsonpal's size, adding a revenue stream nearly three-quarters the size of its current TTM revenue and providing immediate access to institutional doctor networks.
Acquisition Cost: ₹20.8 croreTarget Revenue (FY26): ₹53.31 croreStake Acquired: 85%Target Revenue vs JPL TTM Revenue: ~73%Implied Target Valuation (100%): ₹24.47 crore
📅 Short termThe market is likely to view this as a positive growth move given the significant revenue addition and the strategic expansion into the hospital channel at a reasonable valuation.
📈 Long termStructurally transformative for Jagsonpal, as it diversifies its sales channels and leverages Aequitas' institutional relationships to push its existing branded portfolio into hospitals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Stagnant revenue growth in the target company over the last three years (₹53.7 Cr to ₹53.3 Cr)
- Integration risk of a distribution-led business into a brand-led business
- Potential margin dilution if hospital segment margins are lower than JPL's current 22.3% OPM
Key Highlights
Acquisition of 85% equity stake for a cash consideration of ₹20.8 crore
Target company Aequitas reported FY26 revenue of ₹53.31 crore, showing a slight decline from ₹56.19 crore in FY25
Acquisition cost represents ~28.5% of Jagsonpal's TTM revenue of ₹73 crore
Strategic entry into the hospital segment which currently contributes ~10% of total Indian pharma industry sales
Transaction expected to be completed by July 15, 2026
👀 What to Watch
Watch for the successful completion of the deal by mid-July and subsequent quarterly results to see how the consolidation of Aequitas' ₹53 crore revenue base impacts Jagsonpal's overall margins and working capital.
Jagsonpal Pharma Appoints Former Novartis India CEO Anil Kumar Matai as Independent Director
Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai as an Additional Director in the category of Non-Executive Independent Director for a five-year term starting June 25, 2026. Mr. Matai is a veteran in the life sciences industry with over 35 years of experience, including high-profile roles such as CEO of Novartis India and Managing Director of Zydus Healthcare. He currently serves as the Director General of the Organisation of Pharmaceutical Producers of India (OPPI). This appointment is subject to shareholder approval and is intended to strengthen the board's strategic and regulatory oversight.
Key Highlights
Appointment of Mr. Anil Kumar Matai as Independent Director for a 5-year term effective June 25, 2026.
Mr. Matai brings over 35 years of experience across MNCs, Indian pharma, and private equity sectors.
Previous leadership roles include CEO of Novartis India Ltd and President & MD of Zydus Healthcare Ltd.
Currently holds the position of Director General at the Organisation of Pharmaceutical Producers of India (OPPI).
👀 What to Watch
Investors should view the addition of a high-caliber industry veteran to the board as a positive move for corporate governance and strategic direction. No immediate action is required, but the appointment reinforces confidence in the company's leadership depth.
Jagsonpal Pharma Appoints Former Novartis India CEO Anil Kumar Matai as Independent Director
Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai as an Additional Non-Executive Independent Director for a five-year term effective June 25, 2026. Mr. Matai is a veteran in the life sciences sector with over 35 years of experience, including high-profile roles such as CEO of Novartis India Ltd. and President of Zydus Healthcare Ltd. He currently serves as the Director General of the Organisation of Pharmaceutical Producers of India (OPPI). The appointment is subject to shareholder approval and is expected to strengthen the company's strategic leadership.
Key Highlights
Appointment of Mr. Anil Kumar Matai as Independent Director for a 5-year term starting June 25, 2026.
Brings over 35 years of industry experience across MNCs, Indian pharma, and private equity.
Previously held top leadership positions including CEO of Novartis India and MD of Zydus Healthcare.
Currently serves as Director General of OPPI, focusing on healthcare policy and innovation.
The Board confirmed that the appointee is not debarred from holding office by SEBI or MCA.
👀 What to Watch
Investors should view this as a positive development as it brings high-caliber industry expertise to the board. No immediate action is required, but the addition of a seasoned leader from Novartis and Zydus could improve long-term strategic oversight.
Jagsonpal Pharma Appoints Industry Veteran Anil Kumar Matai as Independent Director for 5 Years
Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai as an Additional Director in the Non-Executive Independent category, effective June 25, 2026. Mr. Matai is a seasoned leader with over 35 years of experience in the life sciences sector, including past roles as CEO of Novartis India and MD of Zydus Healthcare. The appointment is for a 5-year term and is subject to shareholder approval. His current role as Director General of the Organisation of Pharmaceutical Producers of India (OPPI) adds significant regulatory and policy expertise to the board.
Key Highlights
Appointment of Mr. Anil Kumar Matai as Non-Executive Independent Director effective June 25, 2026.
The appointment is for a fixed tenure of 5 years, pending shareholder ratification.
Mr. Matai brings over 35 years of experience across MNCs like Novartis and Indian majors like Zydus.
Currently serves as Director General of OPPI, driving healthcare policy and innovation.
The Board confirmed that the appointee is not debarred by SEBI or any other statutory authority.
👀 What to Watch
Investors should view this as a positive step toward strengthening corporate governance and strategic oversight. No immediate action is required, but the addition of high-caliber leadership is a long-term positive for the company's growth strategy.
Jagsonpal Pharma Extinguishes 16 Lakh Shares; Promoter Stake Rises to 69.36%
Jagsonpal Pharmaceuticals has successfully completed the extinguishment of 16,00,000 equity shares following its buyback via the tender offer route. This action has reduced the company's total paid-up equity share capital from 6,71,39,150 shares to 6,55,39,150 shares. As a result of the reduced share base, the promoter and promoter group's shareholding has increased from 67.71% to 69.36%. The total post-extinguishment share capital stands at approximately ₹13.11 crore.
Key Highlights
Extinguished 16,00,000 equity shares of ₹2 each through a tender offer buyback.
Total issued and paid-up share capital reduced from 6,71,39,150 to 6,55,39,150 equity shares.
Promoter and Promoter Group shareholding increased from 67.71% to 69.36% post-buyback.
The buyback tendering period was conducted between May 8, 2026, and May 14, 2026.
Post-extinguishment share capital value is recorded at ₹13,10,78,300.
👀 What to Watch
Investors should view this as a positive development as the reduction in equity capital typically leads to an improvement in Earnings Per Share (EPS). The increase in promoter holding further signals management's confidence in the company's long-term value.
Jagsonpal Pharma Announces ₹40 Cr Buyback at ₹250/Share via Tender Offer
Jagsonpal Pharmaceuticals is initiating a buyback of 16 lakh shares, which accounts for 2.38% of its total equity. The buyback is priced at ₹250 per share, involving a total outlay of ₹40 crores. This represents 18.35% of the company's combined paid-up capital and free reserves as of March 31, 2025. The tender offer period is scheduled from May 08 to May 14, 2026, following the record date of May 04, 2026.
Key Highlights
Buyback of 16,00,000 shares at ₹250 each, totaling ₹40 crores via tender route
Offer represents 2.38% of total equity and 18.35% of net worth as of March 2025
Entitlement ratio is approximately 7.38% for both small and general category shareholders
Buyback window opens on May 08, 2026, and closes on May 14, 2026
Settlement of bids by Clearing Corporation is expected by May 21, 2026
👀 What to Watch
Eligible shareholders as of the May 04 record date should consider tendering their shares to capitalize on the ₹250 offer price. Investors should monitor the market price relative to the buyback price to assess the premium benefit.
Jagsonpal Pharma Announces ₹40 Crore Buyback at ₹250 Per Share via Tender Offer
Jagsonpal Pharmaceuticals has finalized the details for its buyback of up to 16,00,000 equity shares at a price of ₹250 per share. The total buyback size is ₹40 crore, representing 2.38% of the total equity shares and 18.35% of the company's net worth as of March 2025. The offer will be conducted through the tender route, with the window opening on May 08, 2026, and closing on May 14, 2026. The record date for eligibility was May 04, 2026.
Key Highlights
Buyback price set at ₹250 per share, involving a total outlay of ₹40 crore excluding transaction costs.
The offer includes up to 16,00,000 shares, representing 2.38% of the total paid-up equity capital.
Buyback window is scheduled from May 08, 2026, to May 14, 2026.
Entitlement ratio is approximately 7.38% for both small and general category shareholders.
The buyback size accounts for 18.35% of the aggregate paid-up capital and free reserves as of FY25.
👀 What to Watch
Eligible shareholders should consider tendering their shares if the market price remains significantly below the ₹250 offer price. Long-term investors may benefit from the resulting equity contraction and potential improvement in earnings per share.
Jagsonpal Pharma Q4 FY26 PAT Jumps 31%; Announces ₹40 Cr Buyback and 200% Dividend
Jagsonpal Pharmaceuticals reported a strong recovery in Q4 FY26 with revenue growing 10% YoY to ₹64 crores and PAT surging 31% to ₹9 crores. For the full year FY26, the company outperformed the Indian Pharmaceutical Market (IPM) with a 12.2% MAT growth compared to the industry's 7-8%. The board has approved a ₹40 crore buyback at ₹250 per share and recommended a total dividend of 200% (₹4/share), returning over ₹66 crores to shareholders. Management highlighted improved MR productivity and a strong cash position of over ₹190 crores to support future inorganic growth.
Key Highlights
Q4 FY26 PAT grew 31% YoY to ₹9 crores, while revenue increased 10% to ₹64 crores.
FY26 MAT growth of 12.2% significantly outperformed the IPM growth of 7-8%.
Approved ₹40 crore buyback at ₹250/share with no promoter participation, aiming to boost ROCE to 26%.
Total dividend of 200% (₹4 per share) announced, including a 75% special dividend.
Strong balance sheet with cash reserves exceeding ₹190 crores and a lean 11-day working capital cycle.
👀 What to Watch
Investors should take note of the company's ability to outperform the broader pharma market and its commitment to capital efficiency through buybacks and dividends. The significant improvement in return ratios (ROE/ROCE) makes it a compelling watch in the small-cap pharma space.
Jagsonpal Pharma Sets May 4, 2026, as Record Date for ₹40 Crore Buyback at ₹250/Share
Jagsonpal Pharmaceuticals has finalized May 4, 2026, as the record date for its equity share buyback. The company plans to repurchase up to 16,00,000 shares at a fixed price of ₹250 per share. The total size of the buyback is capped at ₹40 crores, representing a return of surplus cash to shareholders. This corporate action is expected to support the stock price and improve return ratios like ROE and EPS.
Key Highlights
Record date for buyback eligibility fixed as Monday, May 04, 2026
Buyback price set at ₹250 per equity share of face value ₹2 each
Total buyback size of up to 16,00,000 shares amounting to ₹40 crores
The buyback will be conducted on a proportionate basis through the tender offer route
👀 What to Watch
Investors seeking to participate in the buyback must own the shares before the ex-date to be eligible by the May 4 record date. Evaluate the premium of the ₹250 buyback price against the current market price for potential gains.
Jagsonpal Pharmaceuticals Recommends 200% Dividend of Rs 4 Per Share for FY26
The Board of Directors of Jagsonpal Pharmaceuticals has recommended a final dividend of Rs 4 per equity share for the financial year ended March 31, 2026. This payout represents 200% of the face value of Rs 2 per share. The dividend is subject to shareholder approval at the company's 47th Annual General Meeting. Specific dates for the record and payment will be announced separately following the board's recommendation.
Key Highlights
Recommended dividend of Rs 4 per equity share for the financial year 2025-26
Dividend payout represents 200% of the face value of Rs 2 per share
Final approval pending from shareholders at the upcoming 47th Annual General Meeting
Record date and tentative payment date to be intimated separately to the exchanges
👀 What to Watch
Investors should track the announcement of the record date to ensure they hold shares before that date to qualify for the Rs 4 payout. The high dividend percentage reflects a positive stance on capital distribution to shareholders.
